



Trendlines Receives Grant from SIIRD to Begin Clinical Trial in Stress Urinary Incontinence Patients

With support from the Singapore Israel Industrial Research and Development Foundation (SIIRD), Trendlines Labs joins forces with Singapore General Hospital (SGH) on product development and clinical trial of its stress urinary incontinence device

Misgav, Israel; – 29 March 2017 – [Trendlines Labs](#), a business unit of [The Trendlines Group Ltd.](#) (The Trendlines Group) ([SGX: 42T](#); [OTCQX: TRNLY](#)), announced that, in partnership with the [Singapore General Hospital \(SGH\)](#), it will receive a grant from [Singapore Israel Industrial Research and Development Foundation \(SIIRD\)](#) for the development and clinical trial for its Stress Urinary Incontinence (SUI) product. The 50 women in the trial, expected to start mid-2017 at SGH, will provide feedback on the product. SIIRD is providing up to 50% of the US\$400,000 required to fund the final product development and clinical trial.

Trendlines Labs has developed a non-surgical, non-pharmaceutical solution to mitigate SUI, a condition that affects approximately 15 million women in the United States alone¹. The device will provide women who suffer from SUI with a simple-to-use, self-administered home treatment. Trendlines Labs is the in-house innovation center of The Trendlines Group, focused on inventing technologies and products to meet critical unmet market needs.

In the framework of the collaboration agreement, Trendlines Labs and SGH will work together using the technology developed by the Trendlines Labs' team to implement the clinical trial at the SGH facilities, where the management and collection of clinical data will take place. At commercialization of the device, both bodies in the agreement will enjoy royalties from the development.

SGH is the first and largest hospital in Singapore. It is wholly owned by the government of Singapore and the flagship hospital of the country's public healthcare system. SGH seeks to bring its patients new and better care and therapies through research.

Yosi Hazan, CEO of Trendlines Labs, comments: "We're excited to test our SUI device and gain valuable clinical feedback to assist in further development of the product. We hope this partnership with SGH and SIIRD will be a springboard for future projects."

Mr Chan Eng Chye, GM SIIRD, remarked: "We are pleased to support this joint research effort and partnership between Trendlines Labs and SGH to strengthen their capabilities in bringing an important medical device to the market. We look forward to supporting more collaborative R&D projects between medtech companies from Israel and Singapore."

¹ <http://staging.nafc.org/media/media-kit/facts-statistics/>

About The Trendlines Group

[The Trendlines Group](#) is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. The Trendlines Group is traded on the Singapore Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX[®] International (OTCQX: TRNLY).

About The Singapore-Israel Industrial R&D Foundation

The Singapore-Israel Industrial R&D Foundation (SIIRD) is a co-operation between the Singapore Economic Development Board (EDB) and the Israel Innovation Authority to promote, facilitate and support joint industrial R&D projects, between companies from Israel and Singapore, which would lead to successful commercialization. To date, SIIRD has co-funded 152 joint R&D projects between companies from Singapore and Israel.

Investor Contact Information

Israel

Judith Kleinman, Director

Investor Relations & Corporate Communications

judith@trendlines.com

Tel: +972.72.260.7000

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release. This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.

Issuer/Manager THE TRENDLINES GROUP LTD.

Securities THE TRENDLINES GROUP LTD. – IL0011328858 – 42T

Stapled Security No

Announcement Title General Announcement

Date & Time of Broadcast 29 Mar 2017 07:06:55

Status New

Announcement Subtitle Press Release Grant from SIIRD to Begin Clinical
Trial in Stress Urinary Incontinence Patients

Announcement Reference SG170329OTHRA8N6

Submitted By (Co./Ind. Name) Yosef Ron

Designation Joint Company Secretary
